Breast cancer in general can be treated by multiple different treatment modalities, with a great variety of chemotherapeutic, immune modulating, and molecular targeting drugs for each specific kind of subgroup (HER2-positive, HER2-low, hormone receptor-positive, and triple-negative breast cancer). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.